Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2016 1
2017 3
2018 8
2019 17
2020 37
2021 40
2022 28
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

121 results
Results by year
Filters applied: . Clear all
Page 1
Ubrogepant for the Treatment of Migraine.
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Dodick DW, et al. N Engl J Med. 2019 Dec 5;381(23):2230-2241. doi: 10.1056/NEJMoa1813049. N Engl J Med. 2019. PMID: 31800988 Clinical Trial.
METHODS: We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant. We assigned adults with migraine, with or without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a dose of 50 mg, or ubr
METHODS: We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant. We assigned adults …
Ubrogepant.
[No authors listed] [No authors listed] 2020 Oct 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Oct 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33104317 Free Books & Documents. Review.
There is no published experience with ubrogepant during breastfeeding. Ubrogepant is 87% protein bound, so levels in milk are likely low. If ubrogepant is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until mo …
There is no published experience with ubrogepant during breastfeeding. Ubrogepant is 87% protein bound, so levels in milk are …
Ubrogepant.
[No authors listed] [No authors listed] 2021 Jul 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Jul 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 34324284 Free Books & Documents. Review.
Ubrogepant is a small molecule inhibitor of the calcitonin gene-related peptide (CGRP) receptor that blocks the action of CGRP, a potent vasodilator believed to play a role in migraine headaches. Ubrogepant is approved for treatment of acute migraine attacks. In cli
Ubrogepant is a small molecule inhibitor of the calcitonin gene-related peptide (CGRP) receptor that blocks the action of CGRP, a pot
Ubrogepant for the treatment of migraine.
Curto M, Capi M, Cipolla F, Cisale GY, Martelletti P, Lionetto L. Curto M, et al. Expert Opin Pharmacother. 2020 May;21(7):755-759. doi: 10.1080/14656566.2020.1721462. Epub 2020 Feb 3. Expert Opin Pharmacother. 2020. PMID: 32011192 Review.
Long-term non-serious adverse events were similar between placebo and ubrogepant. The efficacy was evaluated in large placebo-controlled studies and ubrogepant 50 mg and 100 mg was superior, even if the therapeutic gain seems to be low. Nevertheless, the favorable s …
Long-term non-serious adverse events were similar between placebo and ubrogepant. The efficacy was evaluated in large placebo-control …
Ubrogepant in the Acute Management of Migraine: A Narrative Review.
Chiang CC, VanderPluym JH. Chiang CC, et al. J Pain Res. 2021 Apr 27;14:1185-1192. doi: 10.2147/JPR.S244249. eCollection 2021. J Pain Res. 2021. PMID: 33948091 Free PMC article. Review.
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that received Food and Drug Administration (FDA) approval for the acute treatment of migraine with and without aura in adults. ...The 52-week open label extension of the Phase III tri
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that received Food and Drug Administration
Ubrogepant: First Approval.
Scott LJ. Scott LJ. Drugs. 2020 Feb;80(3):323-328. doi: 10.1007/s40265-020-01264-5. Drugs. 2020. PMID: 32020557 Free PMC article. Review.
In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine ( aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of …
In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine ( aura) in adults. Thi …
Migraine overview and summary of current and emerging treatment options.
Peters GL. Peters GL. Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34. Am J Manag Care. 2019. PMID: 30681821 Free article. Review.
The newly approved CGRP antagonists are erenumab, fremanezumab, and galcanezumab, while eptinezumab looks to 2020 for approval. Lasmiditan, ubrogepant, and rimegepant are currently emerging acute migraine therapies that may be added to the arsenal of current migraine manag …
The newly approved CGRP antagonists are erenumab, fremanezumab, and galcanezumab, while eptinezumab looks to 2020 for approval. Lasmiditan, …
Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
Nedd M, Garland S, Falk N, Wilk A. Nedd M, et al. Ann Pharmacother. 2022 Mar;56(3):346-351. doi: 10.1177/10600280211023810. Epub 2021 Jun 10. Ann Pharmacother. 2022. PMID: 34109839 Review.
OBJECTIVE: To review the pharmacology, efficacy, and safety of ubrogepant as an abortive migraine treatment. DATA SOURCES: A literature search of MEDLINE and PubMed was performed (January 2006 through May 2021) using the following search terms: ubrogepant, calcitoni …
OBJECTIVE: To review the pharmacology, efficacy, and safety of ubrogepant as an abortive migraine treatment. DATA SOURCES: A literatu …
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Lipton RB, et al. JAMA. 2019 Nov 19;322(19):1887-1898. doi: 10.1001/jama.2019.16711. JAMA. 2019. PMID: 31742631 Free PMC article. Clinical Trial.
Participants were adults with migraine with or without aura experiencing 2 to 8 migraine attacks per month. INTERVENTIONS: Ubrogepant 50 mg (n = 562), ubrogepant 25 mg (n = 561), or placebo (n = 563) for a migraine attack of moderate or severe pain intensity. ...Fur …
Participants were adults with migraine with or without aura experiencing 2 to 8 migraine attacks per month. INTERVENTIONS: Ubrogepant
Ubrogepant to Treat Acute Migraine in Adults.
Edinoff AN, Casey CA, Colon MA, Zaheri AR, Gregoire CM, Bourg MM, Kaye AD, Kaye JS, Kaye AM, Kaye RJ, Tirumala SR, Viswanath O, Urits I. Edinoff AN, et al. Neurol Int. 2021 Jan 28;13(1):32-45. doi: 10.3390/neurolint13010004. Neurol Int. 2021. PMID: 33525313 Free PMC article. Review.
Patients taking Ubrogepant should avoid taking it when pregnant or with end stage renal disease. In summary, Ubrogepant has good tolerability and an overall favorable safety profile. ...
Patients taking Ubrogepant should avoid taking it when pregnant or with end stage renal disease. In summary, Ubrogepant has go …
121 results